B-Cell Non-Hodgkin's Lymphoma
Oncology·MeSH: Lymphoma, B-Cell
Prevalence
30.0 / 100K
4 drugs in development·4 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| hmpl-760 | HUTCHMED (China) Limited (HCM) |
Phase 1(1)
| Drug | Company |
|---|---|
| prt2527 | Prelude Therapeutics Inc (PRLD) |
Phase 1/Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for B-Cell Non-Hodgkin's Lymphoma?
BioSniper tracks 4 drugs in development for B-Cell Non-Hodgkin's Lymphoma across 4 companies.
How many clinical trials target B-Cell Non-Hodgkin's Lymphoma?
There are 2 clinical trials targeting B-Cell Non-Hodgkin's Lymphoma tracked by BioSniper.
What is the prevalence of B-Cell Non-Hodgkin's Lymphoma?
The estimated prevalence of B-Cell Non-Hodgkin's Lymphoma is approximately 30.0 per 100,000 population.
Deep-dive into B-Cell Non-Hodgkin's Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis